Ono Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	509,345	486,871	502,672	447,187	361,361	309,284
Revenue Growth (YoY)	4.52%	-3.14%	12.41%	23.75%	16.84%	5.77%
Cost of Revenue	153,894	147,950	127,126	110,062	93,511	85,573
Gross Profit	355,451	338,921	375,546	337,125	267,850	223,711
Selling, General & Admin	124,450	122,219	97,389	86,643	74,119	66,616
Research & Development	150,858	149,866	112,174	95,344	75,879	62,384
Other Operating Expenses	5,985	1,592	2,807	2,250	4,099	-6,626
Operating Expenses	281,293	277,129	215,251	187,080	157,035	124,988
Operating Income	74,158	61,792	160,295	150,045	110,815	98,723
Interest Expense	-4,866	-1,450	-125	-89	-84	-105
Interest & Investment Income	4,127	4,631	3,574	2,403	2,349	2,462
Earnings From Equity Investments	122	125	1	4	-6	4
Currency Exchange Gain (Loss)	-	-1,861	347	-723	-425	4
Other Non Operating Income (Expenses)	-	21	235	182	399	72
EBT Excluding Unusual Items	73,541	63,258	164,327	151,822	113,048	101,160
Gain (Loss) on Sale of Investments	-	-1,730	-92	-46	-116	122
Gain (Loss) on Sale of Assets	-	-214	-118	-94	-64	-7
Asset Writedown	3,510	-1,981	-51	-498	-316	-2
Legal Settlements	-	-4	-333	-7,652	-7,527	-384
Pretax Income	76,669	59,329	163,733	143,532	105,025	100,889
Income Tax Expense	14,166	9,163	35,694	30,619	24,340	25,392
Earnings From Continuing Operations	62,503	50,166	128,039	112,913	80,685	75,497
Minority Interest in Earnings	-99	-119	-62	-190	-166	-72
Net Income	62,404	50,047	127,977	112,723	80,519	75,425
Net Income to Common	62,404	50,047	127,977	112,723	80,519	75,425
Net Income Growth	-15.70%	-60.89%	13.53%	40.00%	6.75%	26.33%
Shares Outstanding (Basic)	470	470	480	488	496	499
Shares Outstanding (Diluted)	470	470	480	488	497	499
Shares Change (YoY)	0.02%	-2.14%	-1.70%	-1.65%	-0.54%	-0.96%
EPS (Basic)	132.83	106.55	266.61	230.85	162.19	151.11
EPS (Diluted)	132.70	106.41	266.57	230.79	162.16	151.09
EPS Growth	-15.63%	-60.08%	15.50%	42.32%	7.33%	27.56%
Free Cash Flow	119,266	77,028	106,640	154,270	56,332	66,959
Free Cash Flow Per Share	253.85	163.97	222.15	315.90	113.45	134.13
Dividend Per Share	80.000	80.000	80.000	70.000	56.000	50.000
Dividend Growth	-	-	14.29%	25.00%	12.00%	11.11%
Gross Margin	69.79%	69.61%	74.71%	75.39%	74.12%	72.33%
Operating Margin	14.56%	12.69%	31.89%	33.55%	30.67%	31.92%
Profit Margin	12.25%	10.28%	25.46%	25.21%	22.28%	24.39%
Free Cash Flow Margin	23.42%	15.82%	21.21%	34.50%	15.59%	21.65%
EBITDA	111,031	88,686	178,435	167,496	128,536	114,543
EBITDA Margin	21.80%	18.22%	35.50%	37.45%	35.57%	37.04%
D&A For EBITDA	36,873	26,894	18,140	17,451	17,721	15,820
EBIT	74,158	61,792	160,295	150,045	110,815	98,723
EBIT Margin	14.56%	12.69%	31.89%	33.55%	30.67%	31.92%
Effective Tax Rate	18.48%	15.44%	21.80%	21.33%	23.18%	25.17%
Advertising Expenses	-	30,651	24,019	17,837	11,496	6,903

Source: S&P Global Market Intelligence. Standard template. Financial Sources.